Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1.265 INR | +1,11 % | +6,70 % | +16,71 % |
05/06 | Novelis, propiedad de Hindalco, retrasa su OPV en EE.UU.; las acciones caen | RE |
27/05 | Aurobindo Pharma aumenta su beneficio neto consolidado en el cuarto trimestre fiscal | MT |
Resumen de negocios
- medicamentos genéricos: para el tratamiento de enfermedades neurológicas, cardiovasculares, víricas, gastroenterológicas, oftalmológicas y crónicas;
- ingredientes farmacéuticos activos.
A finales de marzo de 2018, el grupo explotaba 23 centros de producción en India (19), Estados Unidos (3) y Brasil.
Las ventas netas se distribuyen geográficamente de la siguiente manera: India (12%), Estados Unidos (46,5%), Europa (31,2%) y otros (10,3%).
Número de empleados: 23 451
Ventas por actividad
INR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Generic Pharmaceuticals and Related Services
97,0
%
| 231 243 | 98,6 % | 241 044 | 97,0 % | +4,24 % |
Services
2,1
%
| 2 422 | 1,0 % | 5 128 | 2,1 % | +111,67 % |
Government Incentive Schemes
0,9
%
| 314 | 0,1 % | 2 176 | 0,9 % | +593,81 % |
Scrap
0,1
%
| 197 | 0,1 % | 207 | 0,1 % | +5,03 % |
Ventas por región
INR en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
45,2
%
| 105 208 | 44,9 % | 112 421 | 45,2 % | +6,86 % |
Europe
29,1
%
| 78 813 | 33,6 % | 72 430 | 29,1 % | -8,10 % |
Rest of the World
14,6
%
| 23 835 | 10,2 % | 36 222 | 14,6 % | +51,97 % |
India
11,1
%
| 26 700 | 11,4 % | 27 482 | 11,1 % | +2,93 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Founder | 66 | 26/12/86 | |
Director of Finance/CFO | - | 01/01/13 | |
B. Adi Reddy
CMP | Compliance Officer | - | 01/06/16 |
Director/Board Member | - | 01/01/16 | |
Corporate Officer/Principal | 68 | 01/02/00 | |
Corporate Officer/Principal | 59 | 01/02/16 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Founder | 66 | 26/12/86 | |
Founder | 66 | 26/12/86 | |
Director/Board Member | 64 | 27/05/03 | |
Director/Board Member | 39 | 27/09/07 | |
Director/Board Member | 67 | 09/02/23 | |
Director/Board Member | 64 | 10/02 | |
Savita Mahajan
BRD | Director/Board Member | 65 | 16/12/17 |
Director/Board Member | 52 | 05/11/20 | |
Director/Board Member | - | 01/01/16 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 585 938 609 | 280 842 785 ( 47,93 %) | 0 | 47,93 % |
Información de la empresa
Aurobindo Pharma Ltd.
Plot No. 1, Hyderabad Knowledge City Raidurg Panmaktha, Galaxy
500032, Hyderabad
+91 40 6672 5000
http://www.aurobindo.comEmpresas del grupo
Nombre | Categoría y sector |
---|---|
Auro Peptides Ltd.
Auro Peptides Ltd. Chemicals: SpecialtyProcess Industries Part of Aurobindo Pharma Ltd., Auro Peptides Ltd. is an Indian company that manufactures peptides. The company is based in Hyderabad, India. |
Chemicals: Specialty
|
Aurozest Pvt Ltd.
| |
Aurobindo Pharma Foundation
|
Investment Trusts/Mutual Funds
|
Eugia Pharma Specialities Ltd.
Eugia Pharma Specialities Ltd. Miscellaneous Commercial ServicesCommercial Services Eugia Pharma Specialities Ltd. develops, manufactures and markets hormonal and oncology generic formulations. The company is headquartered in Hyderabad, India. |
Miscellaneous Commercial Services
|
Qule Pharma Pvt Ltd.
Qule Pharma Pvt Ltd. TextilesProcess Industries Qule Pharma Pvt Ltd. manufactures man-made fibers. The private company is located in India. |
Textiles
|
APL Healthcare Ltd.
APL Healthcare Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurobindo Pharma Ltd., APL Healthcare Ltd. is a fully integrated pharmaceutical company based in Hyderabad, IN. The company also has a strong focus on sustainability and social responsibility, with initiatives in place to ensure compliance with social accountability standards, human rights policies, and progressive health and safety practices. APL Healthcare is dedicated to providing access to healthcare and has programs in place to support this goal. The Indian company offers a range of products and services including formulations, custom synthesis, peptides, and R & D. APL Healthcare is committed to quality and safety, with manufacturing facilities approved by various regulatory bodies including the US FDA, UK MHRA, TGA, MCC-SA, EMA, and ANVISA. |
Pharmaceuticals: Major
|
Apitoria Pharma Pvt Ltd.
| |
Silicon Life Sciences Pvt Ltd.
Silicon Life Sciences Pvt Ltd. Medical SpecialtiesHealth Technology Part of Aurobindo Pharma Ltd., Silicon Life Sciences Pvt Ltd. is an Indian company that manufactures non sterile penems. The company is based in Parawada, India. The company was founded in 2008. Silicon Life Sciences was acquired by Aurobindo Pharma Ltd. on August 10, 2013 for $1.07 million. |
Medical Specialties
|
Auronext Pharma Pvt Ltd.
Auronext Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Aurobindo Pharma Ltd., Auronext Pharma Pvt Ltd. is a pharmaceutical company founded in 2009. The company is based in Hyderabad, India. The Indian company manufactures and supplies pharmaceutical products. |
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+16,71 % | 8782,51 M | |
+45,82 % | 754 mil M | |
+40,95 % | 630 mil M | |
-6,16 % | 352 mil M | |
+19,86 % | 331 mil M | |
+9,32 % | 298 mil M | |
+18,45 % | 250 mil M | |
+11,88 % | 217 mil M | |
-0,78 % | 216 mil M | |
+5,90 % | 164 mil M |
- Bolsa de valores
- Acciones
- Acción AUROPHARMA
- Empresa Aurobindo Pharma